“The US suggestion for the lifting of patent protection for Covid-19 vaccines has significant implications for vaccine production as a whole,” said a government spokeswoman.
“The limiting factors in the production of vaccines are the production capacities and the high quality standards and not patents.”
Berlin said pharmaceutical companies concerned were already working with partners to ramp up manufacturing capacities.
“The protection of intellectual property is a source of innovation and mustremain so in the future,” added the spokeswoman.
Germany is home to BioNTech, the company which co-developed with Pfizer the first Covid vaccine to be approved for use in the West late last year.
Another German company Curevac is in the final stages of its clinical trials and is eyeing authorisation for its Covid jabs in the EU in the coming weeks.
Earlier Thursday, Health Minister Jens Spahn had said Germany backs “the goal of the US president – supplying the world with vaccines is the only way out of the pandemic.”
However those countries that produce vaccines “must also export them to other countries”, Spahn said, pointing to US reticence to allow vaccines to leave its shores.
European Commission President Ursula von der Leyen had earlier said that Brussels was ready to discuss a vaccine patent waiver.
But she also stressed that Europe’s priority would be to boost global supplies, and implicitly criticised both the US and the UK for limiting vaccine exports.